Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Context Therapeutics Inc.
Report date February 15, 2022 · Filed February 17, 2022
Section 16 reporting ended · disclosed 2022-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2032-02-14 | Direct | 8,000 |
Reported balance
After 2022-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 8,000 · Balance 8,000 F1: The stock option vests in equal installments with 1/10th vesting on the date of this grant and each grant thereafter occurring on the last day of each calendar month until fully vested on October 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal installments with 1/10th vesting on the date of this grant and each grant thereafter occurring on the last day of each calendar month until fully vested on October 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 16:48 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001842952-22-000014 · wf-form4_164513451665299.xml · derivative · entry 1 Rencher William F. · CIK 0001865206 · Former Section 16 officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests in equal installments with 1/10th vesting on the date of this grant and each grant thereafter occurring on the last day of each calendar month until fully vested on October 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.